IRONWOOD PHARMACEUTICALS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that IRONWOOD PHARMACEUTICALS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $94.21M | Feb 22, 2018 |
| FY2017 | Sep 30, 2017 | $86.83M | Feb 22, 2018 |
| FY2017 | Jun 30, 2017 | $65.08M | Feb 22, 2018 |
| FY2017 | Mar 31, 2017 | $52.17M | Feb 22, 2018 |
| FY2017 | Dec 31, 2016 | $87.46M | Feb 22, 2018 |
| FY2017 | Sep 30, 2016 | $66.11M | Feb 22, 2018 |
| FY2017 | Jun 30, 2016 | $54.35M | Feb 22, 2018 |
| FY2017 | Mar 31, 2016 | $66.04M | Feb 22, 2018 |
| FY2016 | Dec 31, 2015 | $53.31M | Feb 22, 2017 |
| FY2016 | Sep 30, 2015 | $39.57M | Feb 22, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.71M | Feb 26, 2026 |
| FY2025 | Sep 30, 2025 | $122.06M | Feb 26, 2026 |
| FY2025 | Jun 30, 2025 | $85.24M | Feb 26, 2026 |
| FY2025 | Mar 31, 2025 | $41.14M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $90.55M | Feb 26, 2026 |
| FY2025 | Sep 30, 2024 | $91.59M | Feb 26, 2026 |
| FY2025 | Jun 30, 2024 | $94.40M | Feb 26, 2026 |
| FY2025 | Mar 31, 2024 | $74.88M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $117.55M | Mar 31, 2025 |
| FY2024 | Sep 30, 2023 | $113.74M | Mar 31, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.28M) | Feb 26, 2026 |
| FY2025 | Sep 30, 2025 | $40.08M | Feb 26, 2026 |
| FY2025 | Jun 30, 2025 | $23.60M | Feb 26, 2026 |
| FY2025 | Mar 31, 2025 | ($37.39M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.26M | Feb 26, 2026 |
| FY2025 | Sep 30, 2024 | $3.65M | Feb 26, 2026 |
| FY2025 | Jun 30, 2024 | ($860.0K) | Feb 26, 2026 |
| FY2025 | Mar 31, 2024 | ($4.16M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($1.09M) | Mar 31, 2025 |
| FY2024 | Sep 30, 2023 | $15.32M | Mar 31, 2025 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $98.50M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $93.12M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($945.43M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2022 | $250.34M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $232.26M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $142.94M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $120.12M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | ($150.67M) | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | ($15.36M) | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | ($51.87M) | Feb 25, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $95.14M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $111.42M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $116.09M | Mar 31, 2025 |
| FY2024 | Dec 31, 2022 | $44.27M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $70.41M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $88.06M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $115.04M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $101.06M | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $88.15M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $139.49M | Feb 25, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $82.26M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $144.27M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $158.31M | Mar 31, 2025 |
| FY2024 | Dec 31, 2022 | $115.99M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $111.13M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $140.00M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $172.45M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $219.68M | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $231.18M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $173.28M | Feb 25, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $127.04M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $103.55M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $183.43M | Mar 31, 2025 |
| FY2024 | Dec 31, 2022 | $273.76M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $261.90M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $168.84M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $10.73M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | ($70.88M) | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | ($100.75M) | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | ($25.93M) | Feb 25, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.0K | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $142.0K | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $273.0K | Mar 31, 2025 |
| FY2024 | Dec 31, 2022 | $136.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $265.0K | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $1.84M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $7.19M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $351.0K | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $2.80M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $4.21M | Feb 25, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $396.90M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $350.91M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $471.07M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.10B | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $1.13B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $559.24M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $402.75M | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $332.05M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $605.67M | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $709.82M | Feb 22, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($261.84M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($301.34M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($346.30M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $652.38M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $605.91M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $62.64M | Feb 18, 2022 |
| FY2021 | Dec 31, 2019 | ($93.25M) | Feb 18, 2022 |
| FY2021 | Dec 31, 2018 | ($196.37M) | Feb 18, 2022 |
| FY2020 | Dec 31, 2017 | $9.85M | Feb 17, 2021 |
| FY2019 | Dec 31, 2016 | $66.72M | Feb 13, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $785.0K | Feb 13, 2020 |
| FY2019 | Dec 31, 2018 | $785.0K | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $785.0K | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $785.0K | Feb 22, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.67B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($1.70B) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($1.70B) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($696.38M) | Feb 16, 2024 |
| FY2024 | Dec 31, 2021 | ($937.61M) | Mar 31, 2025 |
| FY2021 | Dec 31, 2020 | ($1.47B) | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | ($1.57B) | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | ($1.59B) | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | ($1.31B) | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | ($1.19B) | Feb 22, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $215.46M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $88.56M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $92.15M | Mar 31, 2025 |
| FY2024 | Dec 31, 2022 | $656.20M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $620.13M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $362.56M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $177.02M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $173.17M | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $125.74M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $54.00M | Feb 25, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $396.25M | Feb 16, 2023 |
| FY2021 | Dec 31, 2021 | $454.19M | Feb 18, 2022 |
| FY2020 | Dec 31, 2020 | $430.26M | Feb 17, 2021 |
| FY2016 | Dec 31, 2015 | $220.62M | Feb 22, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Jun 30, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Mar 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Mar 31, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Jun 30, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Mar 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Mar 31, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 163.06M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 160.21M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 156.35M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 154.03M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | 162.04M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | 160.62M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | 157.54M | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | 154.41M | Feb 13, 2020 |